Prevalence of factor IX inhibitors among patients with haemophilia B: Results of a large-scale North American survey

Haemophilia

Volumn 2, Issue 1, 1996, Pages 28-31

  Katz, Jacob ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bethesda units; Factor IX; Haemophilia B; Inhibitor; Survey; United States

Indexed keywords

BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR;

ARTICLE; AUTOIMMUNITY; CANADA; COMPLICATION; DISEASE SEVERITY; EPIDEMIOLOGY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; UNITED STATES;

EID: 0030062131     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.1996.tb00006.x     Document Type: Article

References (21)

1. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet, 1992; 339: 594-598.
2. Biggs R. Jaundice and antibodies directed against factors VIII and IX in patients treated for haemophilia or Christmas disease in the United Kingdom. Br J Haematol, 1974; 26: 313-329.
3. Shapiro SS, Hultin M. Acquired inhibitors to the blood coagulation factors. Semin Thromb Hemost, 1975; 1: 336-385.
4. Sultan Y, the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost, 1992; 67: 600-602.
5. Thompson AR. Factor IX concentrates for clinical use. Semin Thromb Hemost, 1993; 19: 25-36.
6. Kim HC, Matts L, Eisele J, Czachur M, Saidi P. Monoclonal antibody-purified factor IX: comparative thrombogenicity to prothrombin complex concentrate. Semin Hematol, 1991; 28 (Suppl. 6): 15-19.
7. Mannucci PM, Bauer KA, Gringeri A, et al. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood, 1990; 76: 2540-2545.
8. Mannucci PM, Bauer KA, Grinaeri A, et al. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol, 1991; 79: 606-611.
9. Smith KJ. Factor IX concentrates: the new products and their properties. Transfus Med Rev, 1992; 6: 124-136.
10. Peerlinck K, Rosendaal FR, Vermylen J. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood, 1993; 81: 3332-3335.
11. Bell BA, Kurczynski EM, Bergman G. Inhibitors to monoclonal antibody purified factor VIII. (Letter). Lancet, 1990; 226: 639.
12. Kessler CM, Sachse K. Factor VIII:C inhibitor associated with monoclonal-antibody purified FVIII concentrate. (Letter). Lancet, 1990; 335: 1403.
13. Seremetis S, Aledort L, Lusher J, Hilgartner M, Mannucci PM, Mariani G. Highly purified factor VIII concentrates: will we see more inhibitors? Thromb Haemost, 1991; 65: 1160, Abstract 1672.
14. Peerlinck K, Arnout J, Gilles JG, Saint-Remy J-M, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost, 1993; 69: 115-118.
15. Addiego J, Kasper C, Abildgaard C, et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet, 1993; 342: 462-464.
16. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood, 1993; 81: 2180-2186.
17. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thrombos Diath Haemorrh, 1975; 34: 869-872.
18. Kasper CK. Laboratory tests for factor VIII inhibitors, their variation, significance, and interpretation. Blood Coagul Fibrinolysis, 1991; 2: 7-10.
19. Smit C, Rosendaal FR, Varekamp I, et al. Physical condition, longevity, and social performance of Dutch hemophiliacs, 1972-85. Br Med J, 1989; 298: 235-238.
20. Aledort L. Inhibitors in hemophilia patients: current status and management. Am J Hematol, 1994; 47: 208-217.
21. Saito H. Normal hemostatic mechanisms. In: Disorders of Hemostasis (Ratnoff OD, Forbes CD, eds). New York: Grune & Stratton, 1984; 2: 23-42.